Drugs / PF-04634817
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01791855 | May → Sep 2013 | impaired renal function disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01140672 | Jun → Oct 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01098877 | Apr → Sep 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01994291 | Nov 2013 → Aug 2015 | diabetic macular edema | Pfizer | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01247883 Comparator | Oct → Dec 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01712061 Comparator | Dec 2012 → Sep 2014 | diabetic kidney disease | Pfizer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pf-04634817 | “Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817)” NCT01712061 ↗ |
| Action | Inhibit | “C-C chemokine receptor type 5 antagonist” CHEMBL5095029 ↗1“administration of a CCR2/5 antagonist” NCT01712061 ↗ |
| Modality | Small molecule | — CHEMBL5095029 ↗ |
| Route | Oral | “Oral solution, 1mg, single dose” NCT01098877 ↗ |
| Target | CCR2 | “administration of a CCR2/5 antagonist” NCT01712061 ↗ |
| Target | CCR5 | “C-C chemokine receptor type 5 antagonist” CHEMBL5095029 ↗ |